The results of the quantification and their comparison to the gold standard HPLC-derived values obtained for the same DOX clinical samples is shown in Figure . The samples were run in triplicate. The error between the HPLC and the mean of the TLC-derived values is shown with the error bars representing the standard error of the mean. The FDA guidelines for external diagnostic systems sets 15% as the limit for acceptable performance when comparing to an established method, in this case HPLC. Out of a total of 12 samples studied 9 fit within this ±15% error resulting in a 75% success rate. The other 3 values were close with just ±16% error. This demonstrates the ability of the single mobile phase TLC method to successfully quantify the DOX content with patient plasma and its high level of reliability. The DOL concentration levels were much lower than that of DOX as expected (Figure ). These lower intensity DOL bands increased the variability of DOL quantification and increased the error levels compared to the HPLC-derived values. Here 6 out of the 12 samples were within ±15% error level for a 50% success rate. Those outside the ±15% error range were further away than the DOX values. While less accurate for DOL than for DOX, the TLC method provides clinically valuable DOL concentration estimates. The hermitically sealed, self-contained cartridge design from Figure and 2 was demonstrated using patient plasma samples and the single mobile phase. The calibration curve and the patient samples were successfully loaded onto the TLC plate through the rubber septa access ports using a hypodermic needle.